We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » AZ Grants Brodalumab License to Valeant Pharmaceuticals
AZ Grants Brodalumab License to Valeant Pharmaceuticals
Valeant Pharmaceuticals will pay up to $445 million for the rights to AstraZeneca’s investigational psoriasis drug brodalumab, which is set for regulatory submissions in the U.S. and EU in the fourth quarter.